Blincyto (blinatumomab)

pCPA File Number: 21365

Negotiation Status:

Concluded with an LOI

Indication(s):

Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

PC0204-000

pCPA Engagement Letter Issued:

2020-12-17

Negotiation Process Concluded:

2021-05-21